DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for cervical adenocarcinoma — screening already-approved drugs against its 45-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleCervical adenocarcinoma maps to a 45-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for cervical adenocarcinoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
kelch like ECH associated protein 1 (KEAP1) — KEAP1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 2r,3sdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8IXS · 1.48 Å · ligand (2R,3S)-3-[[(2S)-2-fluoranyl-2-(5,6,7,8-tetrahydronaphthalen-2-yl)ethanoyl]amino]-2-methyl-3-(4-methylphenyl)propanoic acid (T6I). Experimental structure, not a prediction.
What the evidence adds up to
In a 1997 series of four patients with gastric adenocarcinoma metastatic to the uterine cervix, no significant difference in the number of atypical cells or in cell or nuclear diameter was found between primary and metastatic adenocarcinoma. Cell arrangement differed: sheetlike or isolated arrangement was seen frequently in metastatic cervical adenocarcinoma. The authors concluded that cytologic diagnosis of metastatic cervical adenocarcinoma should be made carefully because different cytologic features have been found in past and the present series.
A 2000 case report describes villoglandular papillary adenocarcinoma (VGA) of the cervix, a subset supposedly carrying an excellent prognosis, occurring in young women. The reported patient had classical histological features of VGA but at operation showed tumour cells in the peritoneal wash. A review of 56 cases reported in world literature at that time found occasional cases showing disease spread, suggesting caution in management and follow-up of this entity.
A 2020 whole-exome sequencing study of 24 mainland Chinese patients with cervical adenocarcinoma identified frequently mutated genes and pathways, including PI3K-AKT (KRAS, PIK3CA, PTEN), estrogen signalling (KRAS, PIK3CA, GNAS), and NK cell-mediated antibody-dependent cellular cytotoxicity pathways. Seven patients had HPV infection; mutated genes in HPV-positive tumour tissues were relatively consistent, while mutation profiles of HPV-negative tumour tissues were relatively scattered. The authors suggested the potential for individualized treatment according to genomic information.
What remains missing is any prospective trial testing whether genomic stratification improves outcomes for cervical adenocarcinoma, and any large cohort linking specific mutations to survival or response to existing therapies. The 2020 study had only 24 patients, and no drug was tested. No randomised evidence exists for any targeted agent in this histologic subtype.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Acta Cytologica · 1997 · 17 citations
Cytologic Analysis of Primary Stomach Adenocarcinoma Metastatic to the Uterine Cervix
AbstractOBJECTIVE: To investigate the cytologic and pathologic features of endocervical lesions in cases of gastric adenocarcinoma metastatic to the uterine cervix. STUDY DESIGN: From 1986 to 1994, four patients with gastric adenocarcinoma metastatic to the uterine cervix were treated at our department. The cervical cytologic samples were obtained by swabbing and were stained by the Papanicolaou method. Presence of tumor diathesis, number of atypical cells, cell arrangement, cytoplastic vacuoles, cellular and nuclear diameter, chromatin distribution and size of the nucleolus were investigated. RESULTS: The smear backgrounds were dirty (tumor diathesis) in two cases and clean in two. No significant difference in the number of atypical cells or in cell or nuclear diameter between primary and metastatic adenocarcinoma was shown. Cell arrangement was the different cytologic finding between primary and metastatic adenocarcinoma. Sheetlike or isolated arrangement was seen frequently in metastatic cervical adenocarcinoma. CONCLUSION: Because different cytologic features have been found in past and the present series, cytologic diagnosis of metastatic cervical adenocarcinoma should be made carefully.
Journal of Surgical Oncology · 2000 · 15 citations
Villoglandular papillary adenocarcinoma of the cervix: Case report
AbstractThe incidence of cervical adenocarcinoma is on the rise over the last several decades. It generally carries a worse prognosis than squamous carcinoma. Villoglandular papillary adenocarcinoma (VGA) of the cervix has been identified as a distinct subset of cervical adenocarcinoma that occurs in young women and supposedly carries an excellent prognosis. We report a case of adenocarcinoma of the cervix in a young woman that had classical histological features of VGA but at operation showed presence of tumor cells in the peritoneal wash. A review of world literature on the 56 cases reported so far is presented where occasional cases showing disease spread have been reported, suggesting caution in the management and follow-up of this clinicopathologic entity.
Translational Cancer Research · 2020 · 3 citations · open access
Whole-exome sequencing in cervical adenocarcinoma in mainland Chinese patients
AbstractBackground: Cervical cancer is the most common gynecological malignancy worldwide. Adenocarcinoma is an important pathological type of cervical cancer. In recent years, the incidence of adenocarcinoma is rising in some countries and the prognosis of it remains poor. A precise description of the mutational landscape in cervical adenocarcinoma may provide insights into a better selection of treatments and improve prognosis. Methods: In this study, we conducted whole-exome sequencing (WES) for cervical adenocarcinomas and matched blood samples from a cohort of 24 mainland Chinese patients. Additionally, the Human-Papilloma virus (HPV) infection statuses of these tumor samples were detected, and the genes that were enriched in both HPV positive and negative samples were also analyzed. Results: The results of WES revealed the gene expression profile of cervical adenocarcinoma of women in mainland China and identified multiple genes/pathways, which are frequently mutated in these tumors, including the PI3K-AKT (KRAS, PIK3CA and PTEN), estrogen signaling (KRAS, PIK3CA and GNAS) and NK cell-mediated antibody-dependent cellular cytotoxicity pathways. Besides, seven patients had HPV infection, and the mutated genes in HPV-positive tumor tissues were relatively consistent, while the mutation profiles of HPV-negative tumor tissues were relatively scattered. Conclusions: Taken together, these findings provide novel insights into the pathogenesis of cervical adenocarcinomas. They suggest the potential for individualized treatment of cervical adenocarcinoma according to genomic information.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
